News | March 08, 2022
Industry upbeat on biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The facility will manufacture its Herceptin biosimilar, Tuznue
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Subscribe To Our Newsletter & Stay Updated
